Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Identifieur interne : 001531 ( Main/Corpus ); précédent : 001530; suivant : 001532Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Auteurs : Emin Gemcioglu ; Mehmet Davutoglu ; Ese Ece Ozdemir ; Abdulsamet ErdenSource :
- Multiple sclerosis and related disorders [ 2211-0356 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Anti-Bacterial Agents (therapeutic use), Antimalarials (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (diagnostic imaging), Coronavirus Infections (drug therapy), Coronavirus Infections (physiopathology), Cough (etiology), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunologic Factors (therapeutic use), Interferon-beta (therapeutic use), Length of Stay (MeSH), Male (MeSH), Multiple Sclerosis (complications), Multiple Sclerosis (drug therapy), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnostic imaging), Pneumonia, Viral (drug therapy), Pneumonia, Viral (physiopathology), SARS-CoV-2 (MeSH), Severity of Illness Index (MeSH), Tomography, X-Ray Computed (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antimalarials, Azithromycin, Hydroxychloroquine, Immunologic Factors, Interferon-beta.
- complications : Coronavirus Infections, Multiple Sclerosis, Pneumonia, Viral.
- diagnostic imaging : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Multiple Sclerosis, Pneumonia, Viral.
- etiology : Cough.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Betacoronavirus, COVID-19, Humans, Length of Stay, Male, Pandemics, SARS-CoV-2, Severity of Illness Index, Tomography, X-Ray Computed.
Abstract
BACKGROUND
The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19.
METHODS
In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19.
RESULTS
Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms.
DISCUSSION
This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.
DOI: 10.1016/j.msard.2020.102196
PubMed: 32480326
PubMed Central: PMC7228888
Links to Exploration step
pubmed:32480326Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?</title><author><name sortKey="Gemcioglu, Emin" sort="Gemcioglu, Emin" uniqKey="Gemcioglu E" first="Emin" last="Gemcioglu">Emin Gemcioglu</name><affiliation><nlm:affiliation>Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: egemcioglu@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Davutoglu, Mehmet" sort="Davutoglu, Mehmet" uniqKey="Davutoglu M" first="Mehmet" last="Davutoglu">Mehmet Davutoglu</name><affiliation><nlm:affiliation>Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: mehmetdavutoglu@windowslive.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ozdemir, Ese Ece" sort="Ozdemir, Ese Ece" uniqKey="Ozdemir E" first="Ese Ece" last="Ozdemir">Ese Ece Ozdemir</name><affiliation><nlm:affiliation>Department of Family Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: ese.ece.ozdemir@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Erden, Abdulsamet" sort="Erden, Abdulsamet" uniqKey="Erden A" first="Abdulsamet" last="Erden">Abdulsamet Erden</name><affiliation><nlm:affiliation>Department of Internal Medicine and Division of Rheumatology, Ankara City Hospital, Ankara, Turkey. Electronic address: drsameterden@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32480326</idno><idno type="pmid">32480326</idno><idno type="doi">10.1016/j.msard.2020.102196</idno><idno type="pmc">PMC7228888</idno><idno type="wicri:Area/Main/Corpus">001531</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001531</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?</title><author><name sortKey="Gemcioglu, Emin" sort="Gemcioglu, Emin" uniqKey="Gemcioglu E" first="Emin" last="Gemcioglu">Emin Gemcioglu</name><affiliation><nlm:affiliation>Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: egemcioglu@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Davutoglu, Mehmet" sort="Davutoglu, Mehmet" uniqKey="Davutoglu M" first="Mehmet" last="Davutoglu">Mehmet Davutoglu</name><affiliation><nlm:affiliation>Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: mehmetdavutoglu@windowslive.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ozdemir, Ese Ece" sort="Ozdemir, Ese Ece" uniqKey="Ozdemir E" first="Ese Ece" last="Ozdemir">Ese Ece Ozdemir</name><affiliation><nlm:affiliation>Department of Family Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: ese.ece.ozdemir@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Erden, Abdulsamet" sort="Erden, Abdulsamet" uniqKey="Erden A" first="Abdulsamet" last="Erden">Abdulsamet Erden</name><affiliation><nlm:affiliation>Department of Internal Medicine and Division of Rheumatology, Ankara City Hospital, Ankara, Turkey. Electronic address: drsameterden@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Multiple sclerosis and related disorders</title><idno type="eISSN">2211-0356</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antimalarials (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (diagnostic imaging)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (physiopathology)</term><term>Cough (etiology)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunologic Factors (therapeutic use)</term><term>Interferon-beta (therapeutic use)</term><term>Length of Stay (MeSH)</term><term>Male (MeSH)</term><term>Multiple Sclerosis (complications)</term><term>Multiple Sclerosis (drug therapy)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (diagnostic imaging)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (physiopathology)</term><term>SARS-CoV-2 (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Tomography, X-Ray Computed (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antimalarials</term><term>Azithromycin</term><term>Hydroxychloroquine</term><term>Immunologic Factors</term><term>Interferon-beta</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Multiple Sclerosis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Multiple Sclerosis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cough</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Length of Stay</term><term>Male</term><term>Pandemics</term><term>SARS-CoV-2</term><term>Severity of Illness Index</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms.</p></div><div type="abstract" xml:lang="en"><p><b>DISCUSSION</b></p><p>This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32480326</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-0356</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Multiple sclerosis and related disorders</Title><ISOAbbreviation>Mult Scler Relat Disord</ISOAbbreviation></Journal><ArticleTitle>Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?</ArticleTitle><Pagination><MedlinePgn>102196</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2211-0348(20)30272-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.msard.2020.102196</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gemcioglu</LastName><ForeName>Emin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: egemcioglu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davutoglu</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: mehmetdavutoglu@windowslive.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozdemir</LastName><ForeName>Ese Ece</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: ese.ece.ozdemir@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erden</LastName><ForeName>Abdulsamet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Division of Rheumatology, Ankara City Hospital, Ankara, Turkey. Electronic address: drsameterden@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mult Scler Relat Disord</MedlineTA><NlmUniqueID>101580247</NlmUniqueID><ISSNLinking>2211-0348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest The authors have no conflict of interest about material presented in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32480326</ArticleId><ArticleId IdType="pii">S2211-0348(20)30272-8</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2020.102196</ArticleId><ArticleId IdType="pmc">PMC7228888</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Neurol. 2020 Jun;19(6):481-482</Citation><ArticleIdList><ArticleId IdType="pubmed">32359409</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104791</Citation><ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Sep 12;71(6):1410-1412</Citation><ArticleIdList><ArticleId IdType="pubmed">32301957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001531 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001531 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32480326
|texte= Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32480326" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |